Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder - Trial 2020-004088-26
Access comprehensive clinical trial information for 2020-004088-26 through Pure Global AI's free database. This phase not specified trial is sponsored by Pfizer, Inc. and is currently status unknown. The study focuses on Bipolar Disorder.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Pfizer, Inc.
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
- Any subjects from the preceding double blind trail who experienced a serious adverse event which required study medication to be discontinued and the subject to be withdrawn from the study. Subjects who experienced cardiac arrhythmias, conduction abnormalities, or QTc prolongation (confirmed and persistent Fridericia's correction (QTcF) >480 msec or increase from baseline QTcF >60 msec) during the preceding study.
ICD-10 Classifications
Data Source
EU Clinical Trials Register
2020-004088-26
Non-Device Trial